# US 2026/0062699 A1 · Methods and compositions for modulating splicing at alternative splice sites

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0062699 A1
- Document ID: US20260062699A1
- Status: Published application
- Kind: A1
- Application number: 19/103,514
- Filed: 2023-08-11
- Published: 2026-03-05
- Earliest claimed: 2022-08-12
- Assignees: Remix Therapeutics Inc.
- Applicants: Remix Therapeutics Inc.
- Inventors: Anant A. Agrawal; Frederic Vaillancourt; Zaven Kaprielian; Peter Smith; Alexander S. Harding; Christopher Richer Neil; Maria Sarah Alexis
- Web page: https://patentgrep.com/patent/US20260062699A1

## CPC

- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C12N 2310/11: Antisense
- C12N 2310/315: Phosphorothioates
- C12N 2310/321: 2'-O-R Modification
- C12N 2310/3231: having an additional ring, e.g. LNA, ENA
- C12N 2310/3519: Fusion with another nucleic acid
- C12N 2320/33: Alteration of splicing
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure features bifunctional oligonucleotides and related compositions that, inter alia, modulate nucleic CA acid splicing, e.g., splicing of a pre-mRNA, as well as methods of use thereof.

## Claims

### Claim 1

A bifunctional oligonucleotide comprising:
(i) an alternative splice site targeting sequence capable of binding an exonic element (e.g., 5′ splice site) within a target sequence (e.g., an RNA, e.g., a pre-mRNA or mRNA); and
(ii) a spliceosome targeting sequence capable of binding a spliceosome component (e.g., a U1 snRNP).

### Claim 2 (depends on 1)

The bifunctional oligonucleotide of claim 1, wherein the bifunctional oligonucleotide is a single-stranded oligonucleotide.

### Claim 3 (depends on 1)

The bifunctional oligonucleotide of claim 1, wherein the bifunctional oligonucleotide is an antisense oligonucleotide.

### Claim 4 (depends on 1)

The bifunctional oligonucleotide of claim 1, wherein the bifunctional oligonucleotide is between 25 and 75 nucleotides in length (e.g, between 25 and 70 nucleotides, between 30 and 65 nucleotides, between 40 and 60 nucleotides).

### Claim 5 (depends on 1)

The bifunctional oligonucleotide of claim 1, wherein the bifunctional oligonucleotide is between 5 and 50 nucleotides in length.

### Claim 6 (depends on 1)

The bifunctional oligonucleotide of claim 1, wherein the sequence of (i) is between 5 and 35 nucleotides in length.

### Claim 7 (depends on 1)

The bifunctional oligonucleotide of claim 1, wherein the sequence of (ii) is between 5 and 20 nucleotides in length.

### Claim 8 (depends on 1)

The bifunctional oligonucleotide of claim 1, wherein the sequence of (i) is present at the 5′ terminus of the bifunctional oligonucleotide.

### Claim 9 (depends on 1)

The bifunctional oligonucleotide of claim 1, wherein the sequence of (i) is present at the 3′ terminus of the bifunctional oligonucleotide.

### Claim 10 (depends on 1)

The bifunctional oligonucleotide of claim 1, wherein the sequence of (ii) is present at the 5′ terminus of the bifunctional oligonucleotide.

### Claim 11 (depends on 1)

The bifunctional oligonucleotide of claim 1, the sequence of (ii) is present at the 3′ terminus of the bifunctional oligonucleotide.

### Claim 12 (depends on 1)

The bifunctional oligonucleotide of claim 1, comprising the structure of Formula (I):
or a pharmaceutically acceptable salt thereof, wherein:
the alternative splice site targeting sequence comprises a nucleotide sequence capable of binding to a target sequence (e.g., an RNA, e.g., a pre-mRNA or mRNA) comprising an exonic element (e.g., an alternative splice site);
the spliceosome targeting sequence is a nucleotide sequence capable of binding to a spliceosome component (e.g., U1 snRNP), and
L is absent or a linker.

### Claim 13 (depends on 1)

The bifunctional oligonucleotide of claim 1, comprising the structure of Formula (II):
or a pharmaceutically acceptable salt thereof, wherein:
the alternative splice site targeting sequence comprises a nucleotide sequence capable of binding to a target sequence (e.g., an RNA, e.g., a pre-mRNA or mRNA) comprising an exonic element (e.g., an alternative splice site);
the spliceosome targeting sequence is a nucleotide sequence capable of binding to a spliceosome component (e.g., U1 snRNP), and
L is absent or a linker.

### Claim 14 (depends on 1, 2)

The bifunctional oligonucleotide of claim 1, 2 wherein the bifunctional oligonucleotide comprises a chemical modification (e.g., a non-naturally occurring chemical modification).

### Claim 15 (depends on 14)

The bifunctional oligonucleotide of claim 14, wherein the chemical modification comprises a sugar modification, a nucleobase modification, a terminal modification, or an internucleotide linkage modification.

### Claim 16 (depends on 14, 15)

The bifunctional oligonucleotide of any of claims 14-15, wherein the chemical modification comprises a sugar modification (e.g, a 2′-ribose modification).

### Claim 17 (depends on 16)

The bifunctional oligonucleotide of claim 16, wherein the sugar modification is a 2′-O-alkyl modification, a 2′-halo modification, or a 2′-deoxy modification.

### Claim 18 (depends on 16, 17)

The bifunctional oligonucleotide of any of claims 16-17, wherein the sugar modification comprises a 2′-OMe, 2′-MOE, 2′-H, 2′-Cl, 2′-F modification.

### Claim 19 (depends on 14)

The bifunctional oligonucleotide of claim 14, wherein the chemical modification is a linked nucleic acid (LNA).

### Claim 20 (depends on 14)

The bifunctional oligonucleotide of claim 14, wherein the chemical modification comprises a nucleobase modification (e.g., methylation).

### Claim 21 (depends on 14)

The bifunctional oligonucleotide of claim 14, wherein the chemical modification comprises an internucleotide linkage modification (e.g., a phosphorothioate modification).

### Claim 22 (depends on 4)

The bifunctional oligonucleotide of claim 4, wherein the bifunctional oligonucleotide comprises a plurality of chemical modifications.

### Claim 23 (depends on 1)

The bifunctional oligonucleotide of claim 1, wherein the bifunctional oligonucleotide comprises a chemical modification within (i) and (ii).

### Claim 24 (depends on 1)

The bifunctional oligonucleotide of claim 1, wherein the bifunctional oligonucleotide comprises a plurality of chemical modifications within (i) and (ii).

### Claim 25 (depends on 1)

The bifunctional oligonucleotide of claim 1, wherein the bifunctional oligonucleotide comprises a plurality of sugar modifications or LNAs.

### Claim 26 (depends on 1)

The bifunctional oligonucleotide of claim 1, wherein the bifunctional oligonucleotide comprises at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, or more sugar modifications (e.g., 2′O-Me modifications).

### Claim 27 (depends on 1)

The bifunctional oligonucleotide of claim 1, wherein the bifunctional oligonucleotide comprises at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, or more LNAs.

### Claim 28 (depends on 1)

The bifunctional oligonucleotide of claim 1, comprising the structure of Formula (I-b):
or a pharmaceutically acceptable salt thereof, wherein the alternative splice site targeting sequence is a sequence selected from: AAAAGCAGAACCUGAGCGGC, UUCCAGGGUCGCCATGGCGG, UCAGCUTUUCCAGGGUCGCC, AAGGACTUGAGGGACUCGAA, and AAGGACTUGAGGGACUCGAA; and each of bases 1-33 may be optionally modified with one or modifications selected from: 2′OMe modification, locked nucleic acid modification (LNA), 2′-O-methoxy ethyl modification, and phosphorothioate modification

### Claim 29 (depends on 28)

The bifunctional oligonucleotide of claim 28, wherein the alternative splice site targeting sequence comprises AAAAGCAGAACCUGAGCGGC.

### Claim 30 (depends on 28)

The bifunctional oligonucleotide of claim 28, wherein the alternative splice site targeting sequence comprises UUCCAGGGUCGCCATGGCGG.

### Claim 31 (depends on 28)

The bifunctional oligonucleotide of claim 28, wherein the alternative splice site targeting sequence comprises UCAGCUTUUCCAGGGUCGCC.

### Claim 32 (depends on 28)

The bifunctional oligonucleotide of claim 28, wherein the alternative splice site targeting sequence comprises AAGGACTUGAGGGACUCGAA.

### Claim 33 (depends on 28)

The bifunctional oligonucleotide of claim 28, wherein the alternative splice site targeting sequence comprises UUCAUCAGCUTUUCCAGGGU.

### Claim 34 (depends on 28)

The bifunctional oligonucleotide of claim 28, wherein bases 1-15, 17-19, 21-23, 25-27, 29-31, and 33 comprise a 2′OMe modification; bases 2, 3, 4, and 5 comprise a phosphorothioate modification; and bases 16, 20, 24, 28, and 32 comprise an LNA modification.

### Claim 35 (depends on 28)

The bifunctional oligonucleotide of claim 28, wherein bases 1-15, 17-19, 21-23, 25-27, 29-31, and 33 comprise a 2′OMe modification; bases 30, 31, 32, and 33 comprise a phosphorothioate modification; and bases 16, 20, 24, 28, and 32 comprise an LNA modification.

### Claim 36 (depends on 28)

The bifunctional oligonucleotide of claim 28, wherein bases 1-15, 17-19, 21-23, 25-27, 29-31, and 33 comprise a 2′OMe modification; bases 2, 3, 4, 5, 30, 31, 32, and 33 comprise a phosphorothioate modification; and bases 16, 20, 24, 28, and 32 comprise an LNA modification.

### Claim 37 (depends on 28)

The bifunctional oligonucleotide of claim 28, wherein bases 1-13 comprise a 2′OMe modification; bases 14, 15, 17-19, 21-23, 25-27, 29-31, and 33 comprise a 2′-O-methoxy ethyl modification; bases 30, 31, 32, and 33 comprise a phosphorothioate modification; and bases 16, 20, 24, 28, and 32 comprise an LNA modification.

### Claim 38 (depends on 28)

The bifunctional oligonucleotide of claim 28, wherein bases 1-13 comprise a 2′OMe modification; bases 14, 15, 17-19, 21-23, 25-27, 29-31, and 33 comprise a 2′-O-methoxy ethyl modification; bases 2, 3, 4, 5, 30, 31, 32, and 33 comprise a phosphorothioate modification; and
bases 16, 20, 24, 28, and 32 comprise an LNA modification.

### Claim 39 (depends on 28)

The bifunctional oligonucleotide of claim 28, wherein bases 1, 3, 5, 7, 9, and 11-13 comprise 2′-O-methoxy ethyl modification; bases 14, 15, 17-19, 21-23, 25-27, 29-31, and 33 comprise a 2′OMe modification; bases 2, 3, 4, 5, 30, 31, 32, and 33 comprise a phosphorothioate modification; and bases 2, 4, 6, 8, 10, 16, 20, 24, 28, and 32 comprise an LNA modification.

### Claim 40 (depends on 28)

The bifunctional oligonucleotide of claim 28, wherein bases 1, 3, 5, 7, 9, 11-13, 14, 15, 17-19, 21-23, 25-27, 29-31, and 33 comprise a 2′-O-methoxy ethyl modification; bases 2, 3, 4, 5, 30, 31, 32, and 33 comprise a phosphorothioate modification; and bases 2, 4, 6, 8, 10, 16, 20, 24, 28, and 32 comprise an LNA modification.

### Claim 41 (depends on 28)

The bifunctional oligonucleotide of claim 28, wherein bases 1, 3, 5, 7, 9, and 11-13 comprise 2′-O-methoxy ethyl modification; bases 14, 15, 17-19, 21-23, 25-27, 29-31, and 33 comprise a 2′OMe modification; bases 2, 3, 4, and 5 comprise a phosphorothioate modification; and bases 2, 4, 6, 8, 10, 16, 20, 24, 28, and 32 comprise an LNA modification.

### Claim 42 (depends on 1)

The bifunctional oligonucleotide of claim 1, wherein the alternative splice site (e.g., 5′ splice site) is present within a gene containing a nucleotide repeat expansion.

### Claim 43 (depends on 1)

The bifunctional oligonucleotide of claim 1, wherein the alternative splice site (e.g., 5′ splice site) is present within a gene containing a trinucleotide repeat expansion.

### Claim 44 (depends on 1)

The bifunctional oligonucleotide of claim 1, wherein the alternative splice site (e.g., 5′ splice site) is present within any one of the genes listed in Table 3.

### Claim 45 (depends on 1)

The bifunctional oligonucleotide of claim 1, wherein the alternative splice site (e.g., 5′ splice site) is present within the HTT gene.

### Claim 46 (depends on 1)

The bifunctional oligonucleotide of claim 1, wherein the alternative splice site is present within exon 1 of the HTT gene.

### Claim 47 (depends on 1)

The bifunctional oligonucleotide of claim 1, wherein the alternative splice site within exon 1 is upstream of a CAG region within exon 1.

### Claim 48 (depends on 1)

The bifunctional oligonucleotide of claim 1, wherein the alternative splice site comprises the sequence GAGT (SEQ ID NO: 002) or AAGT (SEQ ID NO: 003).

### Claim 49

The bifunctional oligonucleotide of any of the preceding claims, wherein the U1 snRNP is a wild type U1 snRNP or a variant or fragment thereof.

### Claim 50 (depends on 1)

The bifunctional oligonucleotide of claim 1, wherein the bifunctional oligonucleotide comprises a sequence with at least 75%, 80%, 85%, 90%, 95%, 99%, or more sequence identity with SEQ ID NO: 004, or a variant or fragment thereof.

### Claim 51 (depends on 1)

The bifunctional oligonucleotide of claim 1, wherein the sequence of (ii) comprises a sequence with at least 75%, 80%, 85%, 90%, 95%, 99%, or more sequence identity to SEQ ID NO: 004.

### Claim 52 (depends on 1)

The bifunctional oligonucleotide of claim 1, wherein the sequence of (ii) comprises SEQ ID NO: 004.

### Claim 53 (depends on 1)

The bifunctional oligonucleotide of claim 1, wherein the sequence of the bifunctional oligonucleotide is at least 75%, 80%, 85%, 90%, 95%, 99%, or more sequence identity with an oligonucleotide listed in Table 1 or 2, e.g., an oligonucleotide selected from SEQ ID NOs: 100-254, or a variant or fragment thereof.

### Claim 54 (depends on 1)

The bifunctional oligonucleotide of claim 1, wherein the sequence of (i) comprises a sequence with at least 75%, 80%, 85%, 90%, 95%, 99%, or more sequence identity with a nucleotide selected from SEQ ID NOs: 100-254, or a variant or fragment thereof.

### Claim 55 (depends on 1)

The bifunctional oligonucleotide of claim 1, wherein the sequence of (i) comprises a sequence selected from SEQ ID NOs: 100-254, or a variant or fragment thereof.

### Claim 56

A bifunctional oligonucleotide comprising:
(i) a nucleotide sequence capable of binding to a splice site (e.g., 5′ splice site) within exon 1 of the HTT gene, wherein the nucleotide sequence comprises a plurality of chemical modifications (e.g., a plurality of 2′OMe modifications and LNA modifications) and is between 5 and 35 nucleotides in length; and
(b) a nucleotide sequence capable of binding an U1 snRNA comprising a plurality of chemical modifications (e.g., a plurality of 2′OMe modifications).

### Claim 57 (depends on 1, 56)

The bifunctional oligonucleotide of claim 1 or 56, wherein the bifunctional oligonucleotide is capable of one or more of:
(a) enhancing exonization of the HTT gene (e.g., exon 1) by recruiting the U1 snRNP to an alternative 5′ splice site;
(b) altering the sequence of the HTT gene (e.g., exon 1) by recruiting the U1 snRNP to an alternative 5′ splice site; and
(b) potentiating U1 usage/recruitment.

### Claim 58 (depends on 57)

The bifunctional oligonucleotide of claim 57, comprising (a).

### Claim 59 (depends on 57)

The bifunctional oligonucleotide of claim 57, comprising (b).

### Claim 60 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59)

A pharmaceutical composition comprising a bifunctional oligonucleotide of any of claims 1-59.

### Claim 61 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59)

The bifunctional oligonucleotide of any of claims 1-59, disposed in a delivery vehicle.

### Claim 62 (depends on 61)

The bifunctional oligonucleotide of claim 61, wherein the delivery vehicle is a membrane-bound delivery vehicle.

### Claim 63 (depends on 61)

The bifunctional oligonucleotide of claim 61, wherein the delivery vehicle comprises a liposome or lipid nanoparticle.

### Claim 64

A method of modulating the production or level of a transcription product in a cell or subject comprising an exonic element (e.g., a trinucleotide expansion, e.g., a [CAG]n site) in a subject or cell, wherein:
(i) the exonic element is flanked by a proximal splice site and a distal splice site, and
(ii) the proximal splice site and distal splice sites are both 5′ splice sites or are both 3′ splice sites;
comprising contacting said cell or subject with a bifunctional oligonucleotide promoting splicing at:
(a) the distal 5′ splice site to (a-i) decrease the production or level of a transcription product comprising the exonic element or (a-ii) increase the production or level of a transcription product lacking the exonic element; or
(b) the proximal 3′ splice site to (b-i) increase the production or level of a transcription product comprising the exonic element or (b-ii) decrease the production or level of a transcription product lacking the exonic element;
thereby modulating the production or level of a transcription product comprising an exonic element (e.g., a trinucleotide expansion, e.g., a [CAG], site).

### Claim 65 (depends on 64)

The method of claim 64, comprising (a-i) or (a-ii).

### Claim 66 (depends on 64)

The method of claim 64, comprising (a-i).

### Claim 67 (depends on 64)

The method of claim 64, comprising (b-i) or (b-ii).

### Claim 68 (depends on 64)

The method of claim 64, comprising (b-i).

### Claim 69 (depends on 64, 65, 66, 67, 68)

The method of any of claims 64-68, wherein, the distal 5′ splice site is a non-canonical 5′ splice site.

### Claim 70 (depends on 64, 65, 66, 67, 68, 69)

The method of any of claims 64-69, wherein the proximal 5′ splice site is a canonical 5′ splice site.

### Claim 71 (depends on 64, 65, 66, 67, 68, 69, 70)

The method of any of claims 64-70, wherein the distal 5′ splice site is a non-canonical 5′ splice site and the exonic element comprises a canonical 5′ spice site.

### Claim 72 (depends on 64, 65, 66, 67, 68, 69, 70, 71)

The method of any of claims 64-71, wherein the exonic element comprises a trinucleotide repeat.

### Claim 73 (depends on 72)

The method of claim 72, wherein the trinucleotide repeat comprises the nucleotide sequence CXY, wherein each of X and Y is selected from A, T, G, and C.

### Claim 74 (depends on 72)

The method of claim 72, wherein the trinucleotide repeat is selected from CAG, CGG, or CGG.

### Claim 75 (depends on 64)

The method of claim 64, wherein the alternative splice site is the 5′ distal splice site.

### Claim 76 (depends on 64)

The method of claim 64, wherein the production or level of a transcription product produced by splicing at the distal 5′ splice site is increased by at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or more, e.g., in comparison to a reference standard (e.g., the transcription product produced by splicing at proximal 5′ splice site, wild type transcription product, mutant transcription product, etc).

### Claim 77 (depends on 64)

The method of claim 64, wherein the production or level of a transcription product produced by splicing at the proximal 5′ splice site is decreased by at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or more, e.g., in comparison to a reference standard (e.g., the transcription product produced by splicing at distal 5′ splice site, wild type transcription product, mutant transcription product, etc).

### Claim 78 (depends on 64)

The method of claim 64, wherein the exonic element is flanked by a plurality of distal splice sites, e.g., distal 5′ splice sites.

### Claim 79 (depends on 64)

The method of claim 64, wherein the exonic element is flanked by a plurality of proximal splice sites, e.g., proximal 5′ splice sites.

### Claim 80 (depends on 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79)

The method of any one of claims 64-79, wherein the ratio of:
(A) the production or level of a transcription product arising from splicing at the 5′ distal splice site (e.g., a less-favored, less efficient, or non-canonical splice site) to
(B) the production or level of a transcription product arising from splicing at the 5′ proximal splice site (e.g., a more-favored, more efficient, or a canonical splice site),
is between 1:1-10:1, or 1:1-1:10.

### Claim 81 (depends on 80)

The method of claim 80, wherein the ratio of (A) to (B) is decreased by the modulating.

### Claim 82 (depends on 80)

The method of claim 80, wherein the decrease of the ratio of (A) to (B) is about 5%, 10% 15%, 20% 25%, 30%, 35%, 40%, 45%, 50%, or more.

### Claim 83 (depends on 80)

The method of claim 80, wherein the ratio of (A) to (B) is lower at one allele or chromosome (e.g., a mutant allele, e.g., an allele comprising a tri-nucleotide repeat) than at the other allele or chromosome (e.g., a non-mutant allele, e.g., an allele not comprising a tri-nucleotide repeat).

### Claim 84 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 80)

The method of claim 80, wherein the bifunctional oligonucleotide is a bifunctional oligonucleotide of any one of claims 1-45.

### Claim 85 (depends on 80)

The method of claim 80, wherein the production or level of a transcription product produced by splicing at the distal 5′ splice site is increased by at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, e.g., in comparison to a cell or subject not administered the bifunctional oligonucleotide.

### Claim 86 (depends on 80, 81, 82, 83, 84, 85)

The method of any one of claims 80-85, wherein the production or level of a transcription product produced by splicing at the proximal 5′ splice site is decreased by at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, e.g., in comparison to a cell or subject not administered the bifunctional oligonucleotide.

### Claim 87 (depends on 80, 81, 82, 83, 84, 85, 86)

The method of any one of claims 80-86, wherein the bifunctional oligonucleotide has one or more of the following properties:
(i) is capable of binding at or near to a distal 5′ splice site or a distal 3′ splice site;
(ii) is capable of binding at or near to a U1 snRNP (e.g., a mutant U1 snRNP); and
(iii) is capable of promoting splicing of a mutant pre-mRNA relative to a wild-type pre-mRNA.

### Claim 88 (depends on 80, 81, 82, 83, 84, 85, 86, 87)

The method of any one of claims 80-87, wherein the exonic element comprises the nucleotide sequence [CAG]n, wherein n is an integer between 10 and 60.

### Claim 89 (depends on 80)

The method of claim 80, wherein the nucleotide sequence [CAG]n forms a double-stranded structure (e.g., hairpin structure).

### Claim 90 (depends on 80)

The method of claim 80, wherein the modulating is dependent on the length of the nucleotide sequence [CAG]n.

### Claim 91 (depends on 80)

The method of claim 80, wherein the transcription product is an HTT mRNA.

### Claim 92 (depends on 80)

The method of claim 80, wherein the exonic element is present within an exon of the HTT gene.

### Claim 93 (depends on 80)

The method of claim 80, wherein the exonic element is present within exon 1 of the HTT gene.

### Claim 94 (depends on 80)

The method of claim 80, wherein the distal 5′ splice site is present within exon 1 of the HTT gene.

### Claim 95 (depends on 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80)

The method of any one of claims 50-80, wherein the proximal splice site and the distal splice site are 3′splice sites.

### Claim 96 (depends on 81)

The method of claim 81, comprising promoting splicing at the distal 3′ splice site to decrease the production or level of a transcription product comprising the exonic element.

### Claim 97 (depends on 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96)

The method of any one of claims 80-96, comprising promoting splicing at the distal 3′ splice site to increase the production or level of a transcription product that lacks the exonic element.

### Claim 98 (depends on 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97)

The method of any one of claims 80-97, wherein the distal splice site is a non-canonical 3′ splice site.

### Claim 99 (depends on 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98)

The method of any one of claims 80-98, wherein the proximal splice site is a canonical 3′ splice site.

### Claim 100 (depends on 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99)

The method of any one of claims 80-99, wherein the distal splice site is a non-canonical 3′ splice site and the gene comprises a canonical 3′ splice site disposed between the exonic element and cognate intron of the canonical 3′ splice site.

### Claim 101 (depends on 100)

The method of claim 100, comprising promoting splicing at the proximal splice site to increase the production of a transcription product comprising the exonic element.

### Claim 102 (depends on 100)

The method of claim 100, comprising promoting splicing at the proximal splice site to decrease the production or level of a transcription product lacking the exonic element.

### Claim 103 (depends on 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102)

The method of any of claims 80-102, wherein a first and second allele of the gene are present.

### Claim 104 (depends on 103)

The method of claim 103, wherein the first allele is carried on a first chromosome and the second allele is carried on a second chromosome.

### Claim 105 (depends on 89, 90)

The method of any of claims 89-90, wherein the sequence of the exonic element of one allele differs from the sequence of the exonic element on the second allele.

### Claim 106 (depends on 89, 90, 91)

The method of any of claims 89-91, wherein one allele comprises the exonic element and the other allele does not comprise the exonic element.

### Claim 107 (depends on 89, 90, 91, 92)

The method of any of claims 89-92, wherein
(i) a transcription product comprising a first form of the exonic element, e.g., a [CAG]n, is transcribed from an allele on a first chromosome; and
(ii) a transcription product which lacks the first form of the exonic element, is transcribed from an allele on a second chromosome.

### Claim 108 (depends on 89, 90, 91, 92, 93)

The method of any of claims 89-93, where one of the alleles on the first and second chromosome is wild type for the gene which is not disease-associated and the other is mutant or disease associated allele for the gene.

### Claim 109 (depends on 108)

The method of claim 108, performed in vitro.

### Claim 110 (depends on 108)

The method of claim 108, performed in vivo.

### Claim 111 (depends on 108, 109, 110)

The method of any of claims 108-110, wherein splicing of the distal splice site is more efficient than is splicing of the proximal splice site.

### Claim 112

A method of modulating splicing at an alternative splice site (e.g., a flanking an exonic element, e.g., a trinucleotide expansion, e.g., a [CAG],I site) wherein:
(i) the exonic element is flanked by a proximal splice site a distal splice site, and
(ii) the proximal splice site and distal splice sites are both 5′ splice sites or are both 3′ splice sites;
comprising
(a) (i) wherein the alternative splice site is the 5′ distal splice site, promoting splicing at the 5′ distal splice site, or
(b) (i) wherein the alternative splice site is the 3′ distal splice site, promoting splicing at the proximal 3′splice site;
thereby modulating splicing at an alternative splice site.

### Claim 113 (depends on 112)

The method of claim 112, wherein the exonic element comprises a trinucleotide repeat.

### Claim 114 (depends on 112)

The method of claim 112, wherein the trinucleotide repeat comprises the nucleotide sequence CXY, wherein each of X and Y is selected from A, T, G, and C.

### Claim 115 (depends on 112)

The method of claim 112, wherein the trinucleotide repeat is selected from CAG, CGG, or CGG.

### Claim 116 (depends on 112, 113, 114, 115)

The method of any one of claims 112-115, wherein the alternative splice site is the 5′ distal splice site.

### Claim 117 (depends on 112, 113, 114, 115, 116)

The method of any one of claims 112-116, wherein the alternative splice site is the 3′ distal splice site.

### Claim 118

A method of modulating splicing at an alternative splice site within the HTT gene in a subject or cell, wherein the HTT gene comprises a [CAG]n site and the splice site is present upstream of the [CAG]n site.

### Claim 119 (depends on 118)

The method of claim 118, comprising administering to the subject or cell an exogenous modulator.

### Claim 120

A method of treating a trinucleotide repeat expansion disease comprising modulating splicing at an alternative splice site in a subject, wherein the alternative splice site is flanking an exonic element (e.g., a trinucleotide expansion, e.g., a [CAG]n site) wherein:
(i) the exonic element is flanked by a proximal splice site a distal splice site, and
(ii) the proximal splice site and distal splice sites are both 5′ splice sites or are both 3′ splice sites;
comprising
(a) (i) wherein the alternative splice site is the 5′ distal splice site, promoting splicing at the 5′ distal splice site, or
(b) (i) wherein the alternative splice site is the 3′ distal splice site, promoting splicing at the proximal 3′splice site;
thereby treating a trinucleotide repeat expansion disease.

### Claim 121 (depends on 1, 120)

A method of treating a trinucleotide repeat expansion disease, comprising administering to a subject a bifunctional oligonucleotide of any one of claims 1-120, or a composition thereof.

### Claim 121 (depends on 1, 120)

A composition for use in treating a trinucleotide repeat expansion disease, comprising a bifunctional oligonucleotide of any one of claims 1-120.
